MX2023007293A - Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral. - Google Patents
Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral.Info
- Publication number
- MX2023007293A MX2023007293A MX2023007293A MX2023007293A MX2023007293A MX 2023007293 A MX2023007293 A MX 2023007293A MX 2023007293 A MX2023007293 A MX 2023007293A MX 2023007293 A MX2023007293 A MX 2023007293A MX 2023007293 A MX2023007293 A MX 2023007293A
- Authority
- MX
- Mexico
- Prior art keywords
- antitumor
- drug
- induction
- antiviral
- immunty
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 230000006698 induction Effects 0.000 title abstract 2
- 108010011730 CIGB-300 Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000036039 immunity Effects 0.000 abstract 2
- 230000037449 immunogenic cell death Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Uso del péptido identificado como SEQ ID No: 1 para la fabricación de un medicamento para la inducción de inmunidad antitumoral y antiviral mediada por la muerte celular inmunogénica; la invención también provee un método para el tratamiento del cáncer o de infecciones virales que se caracteriza porque se administra a un individuo que lo necesita una cantidad terapéuticamente efectiva de un medicamento para la inducción de inmunidad antitumoral y antiviral, la que está mediada por la muerte celular inmunogénica, donde el medicamento comprende dicho péptido sintético; es también parte de la invención una combinación farmacéutica que comprende el péptido identificado como SEQ ID No: 1 y una vacuna para la inmunoterapia del cáncer, la que logra un abordaje inmunoterapéutico más efectivo de esta enfermedad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
| PCT/CU2021/050013 WO2022127945A2 (es) | 2020-12-18 | 2021-11-23 | Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007293A true MX2023007293A (es) | 2023-07-04 |
Family
ID=80683707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007293A MX2023007293A (es) | 2020-12-18 | 2021-11-23 | Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240082392A1 (es) |
| EP (1) | EP4265268A2 (es) |
| JP (1) | JP2023554401A (es) |
| KR (1) | KR20230122063A (es) |
| CN (1) | CN116963758A (es) |
| AU (1) | AU2021403339A1 (es) |
| BR (1) | BR112023011605A2 (es) |
| CA (1) | CA3201752A1 (es) |
| CU (1) | CU20200103A7 (es) |
| MX (1) | MX2023007293A (es) |
| WO (1) | WO2022127945A2 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2020
- 2020-12-18 CU CU2020000103A patent/CU20200103A7/es unknown
-
2021
- 2021-11-23 BR BR112023011605A patent/BR112023011605A2/pt unknown
- 2021-11-23 AU AU2021403339A patent/AU2021403339A1/en active Pending
- 2021-11-23 US US18/268,118 patent/US20240082392A1/en active Pending
- 2021-11-23 WO PCT/CU2021/050013 patent/WO2022127945A2/es active Application Filing
- 2021-11-23 EP EP21865362.4A patent/EP4265268A2/en active Pending
- 2021-11-23 JP JP2023536436A patent/JP2023554401A/ja active Pending
- 2021-11-23 KR KR1020237023660A patent/KR20230122063A/ko unknown
- 2021-11-23 CA CA3201752A patent/CA3201752A1/en active Pending
- 2021-11-23 MX MX2023007293A patent/MX2023007293A/es unknown
- 2021-11-23 CN CN202180093881.4A patent/CN116963758A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021403339A1 (en) | 2023-07-06 |
| CA3201752A1 (en) | 2022-06-23 |
| CN116963758A (zh) | 2023-10-27 |
| EP4265268A2 (en) | 2023-10-25 |
| WO2022127945A2 (es) | 2022-06-23 |
| KR20230122063A (ko) | 2023-08-22 |
| US20240082392A1 (en) | 2024-03-14 |
| WO2022127945A3 (es) | 2022-12-22 |
| JP2023554401A (ja) | 2023-12-27 |
| BR112023011605A2 (pt) | 2023-10-31 |
| CU20200103A7 (es) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021018694A2 (pt) | Vesículas extracelulares para distribuição de vacina | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PH12020500078A1 (en) | Anti-ctla-4 antibodies and uses thereof | |
| BR112017003108A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
| PH12015502629B1 (en) | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment | |
| MX2023014457A (es) | Peptidos antigenicos para la prevencion y el tratamiento del cancer. | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| MX2016002937A (es) | Vacuna oncologica. | |
| ZA202202174B (en) | Method for treating diseases based on interferon | |
| TN2018000021A1 (en) | ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY. | |
| BR112017005120A2 (pt) | composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo | |
| MX2020009150A (es) | Anfifilos de cpg y usos de los mismos. | |
| MX2021010766A (es) | Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos. | |
| SE0300034L (sv) | Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer | |
| MX2023007293A (es) | Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral. | |
| JP2017522326A5 (es) | ||
| TN2011000459A1 (en) | Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases | |
| PH12016502042A1 (en) | Drug delivery conjugates for treating resistant cancer and for use in combination therapy | |
| MX2020007050A (es) | Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. | |
| MX2020001055A (es) | Vacuna contra la malaria. | |
| MX2011012659A (es) | Terapia con vacunas para neovascularizacion coroidea. | |
| MX2021003660A (es) | Composicion inyectable. | |
| MX2021014353A (es) | Adyuvantes de vacunas basados en ligandos de receptores tlr. | |
| MX2021015643A (es) | Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral. |